MUC1 and neoplasm: Microvesicles derived from tumors, carrying the MUC1 tumor glycoantigen, could be utilized to pulse DCs and activate an IFN-γ response mediated by MUC1-specific CD8+ T cells, ultimately promoting an antitumor response (163).